菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Expert Viral Clearance Studies

Rapid, Reliable Biosafety Testing to Ensure Safety and Compliance

 

Viral clearance studies are critical for IND and BLA submissions. WuXi Biologics offers rapid, reliable service backed by over 1,400 studies and Biosafety Level 2 labs. We support antibodies, recombinant proteins, vaccines, viral vectors, and antibody-drug conjugates, along with animal extracts, medical devices, and more. With immediate capacity, competitive pricing, and seamless partnership, we help you secure global compliance.

 

Scroll Down for Details

 

 

Trusted Partnerships


 

Case Study: Superior Viral Clearance Maximizes Product Safety


High log10 reduction values (LRVs) are essential to ensuring the safety of biologic products. With WuXi Biologics’ advanced viral clearance studies, you can enhance sensitivity and maximize LRVs for a robust, regulatory-compliant manufacturing process.    

 

To help a client achieve superior viral clearance while optimizing cost efficiency, we combined large-volume testing with multiple quantitative virus detection methods—including plaque assay, TCID50, and qPCR. This comprehensive approach increased confidence in product safety, strengthened regulatory filings, and streamlined the path to market.    

 

How can our innovation benefit your project?  

 

Find Out Now

 

Factors for Your Success


  • Accelerated Timelines
    IND filing in only 2 months; BLA filing in 3 months

     

  • Proven Excellence
    Passed EMA, PMDA, and NMPA inspections; an FDA remote regulatory assessment; and EMA GMP, CNAS certifications, also obtaining GMP clearance from TGA and Health Canada

     

  • Established Infrastructure
    Over 400 biosafety experts and GMP labs with advanced technology

     

  • Strict Confidentiality
    Twelve distinct labs with robust IP protection and data integrity systems

     

  • No Operational Burden
    Comprehensive studies conducted entirely by WuXi Biologics

     

  • Validated Methods
    Plaque assay, TCID50, qPCR, and more, validated per ICH Q2 guidelines for quantitative virus detection

 

Meeting Safety and Regulatory Standards


We make sure you meet all viral clearance requirements. After the IND stage, which prioritizes safety for early clinical trials, we expand testing for BLA submission.

 

IND Stage for CHO Cell-Derived Products

Step Retrovirus (X-MuLV) Parvovirus (MVM)
Viral inactivation Duplicate experiments on one lot sample Not applicable
Viral filtration Duplicate experiments on one lot sample
Chromatography Duplicate experiments on one lot sample

 

 

BLA Stage for CHO Cell-Derived Products

Step Retrovirus (X-MuLV) Parvovirus (MVM) Herpesvirus (PrV) Reovirus (Reo-3)
Viral inactivation Duplicate experiments on one lot sample Not applicable One lot per sample, tested in duplicates Not applicable
Viral filtration Duplicate experiments on one lot sample
Chromatography with mass balance
New resin Duplicate experiments on one lot sample
Aged resin Duplicate experiments on one lot sample
Carryover (new and aged resin) Duplicate experiments on one lot sample

  Ready to validate? We’re ready to help.  

 

Connect with Our Experts

 

Comprehensive Biosafety Testing


Cell bank characterization and unprocessed bulk (UPB) release testing are also critical to biosafety. WuXi Biologics offers a full suite of biosafety testing services, that meet international standards, covering every stage of development and manufacturing.

 

Cell Bank Characterization

Cell bank characterization ensures the identity, purity, stability, and safety of master and working cell banks, forming a robust foundation for production. With over 2,500 characterizations completed, WuXi Biologics draws on exceptional expertise.

 

For both mammalian and microbial cell banks, we provide comprehensive testing:

 

  • Gene stability
  • Authenticity and species identity
  • Sterility and mycoplasma detection
  • Adventitious virus screening with an in vitro assay or next-generation sequencing (NGS)
  • Retrovirus test
  • Specific virus detection with PCR or NGS
  • Animal-based virus testing assay or replacement NGS

UPB Release Testing

After upstream production, UPB release testing confirms the safety of bulk drug substances for seamless downstream processing. Our lab meets U.S., EU, and China regulatory standards.

 

Our dedicated team brings fast timelines and proven reliability to UPB release testing:

 

  • Bioburden
  • Mycoplasma detection
  • Adventitious virus screening with an in vitro assay
  • Quantitation of retrovirus particles with transmission electron microscopy
  • Specific virus detection with PCR or NGS
  • Nucleic acid test-based quick-release panel

Related Resources
Biosafety Testing Services